Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to a noncoding RNA transcript antisense to MARVELD3 (ENSG00000260593). The transcript does not encode a protein and is classified as a noncoding variant located near the MARVELD3 locus. Its function is undetermined, but antisense transcripts can sometimes regulate expression of their sense counterparts through RNA interference or other mechanisms. MARVELD3 itself encodes a tight junction-associated transmembrane protein with roles in epithelial barrier function, cell migration, and cancer biology[1][2][4][5]. No therapeutic drugs, biomarkers, or significant molecular mediators are documented for this antisense transcript. No molecular family (e.g., receptor, ion channel, transporter, enzyme) is assigned to this locus. Key Point: ENSG00000260593 is an antisense, noncoding transcript—not a canonical drug target or receptor. The drug target MARVELD3 is a distinct protein-coding gene associated with epithelial tight junctions, with possible roles in cancer biology. If you seek information about the protein target MARVELD3 itself, you should focus searches on that gene, not its antisense transcript[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to MARVELD3 (ENSG00000260593).